PT1481057E - Sistema e metodo para a producao de proteinas glicosiladas recombinantes num hospedeiro procariota - Google Patents

Sistema e metodo para a producao de proteinas glicosiladas recombinantes num hospedeiro procariota

Info

Publication number
PT1481057E
PT1481057E PT03702276T PT03702276T PT1481057E PT 1481057 E PT1481057 E PT 1481057E PT 03702276 T PT03702276 T PT 03702276T PT 03702276 T PT03702276 T PT 03702276T PT 1481057 E PT1481057 E PT 1481057E
Authority
PT
Portugal
Prior art keywords
recombinant
production
proteins
procariot
glycosilate
Prior art date
Application number
PT03702276T
Other languages
English (en)
Inventor
Aebi Markus
Wacker Michael
Original Assignee
Eidgenoess Tech Hochschule
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eidgenoess Tech Hochschule filed Critical Eidgenoess Tech Hochschule
Publication of PT1481057E publication Critical patent/PT1481057E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/005Glycopeptides, glycoproteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549Sugars, nucleosides, nucleotides or nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/121Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT03702276T 2002-03-07 2003-03-05 Sistema e metodo para a producao de proteinas glicosiladas recombinantes num hospedeiro procariota PT1481057E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH3942002 2002-03-07
US36465502P 2002-03-14 2002-03-14

Publications (1)

Publication Number Publication Date
PT1481057E true PT1481057E (pt) 2006-05-31

Family

ID=27789602

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03702276T PT1481057E (pt) 2002-03-07 2003-03-05 Sistema e metodo para a producao de proteinas glicosiladas recombinantes num hospedeiro procariota

Country Status (12)

Country Link
US (3) US20050287628A1 (pt)
EP (1) EP1481057B1 (pt)
KR (1) KR20090110951A (pt)
AT (1) ATE317897T1 (pt)
AU (1) AU2003205502C1 (pt)
CA (1) CA2477794C (pt)
DE (1) DE60303591T2 (pt)
DK (1) DK1481057T3 (pt)
ES (1) ES2258214T3 (pt)
IL (3) IL163806A0 (pt)
PT (1) PT1481057E (pt)
WO (1) WO2003074687A1 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090110951A (ko) 2002-03-07 2009-10-23 아이드게노쉬쉐 테흐니쉐 호흐슐레 쥬리히 원핵 숙주에서의 재조합 글리코실화 단백질 생산 방법 및 생산계
AU2011218682B2 (en) * 2005-05-11 2013-11-21 Eth Zurich Recombinant N-glycosylated proteins from procaryotic cells
CA2607595C (en) 2005-05-11 2018-11-27 Eth Zuerich Recombinant n-glycosylated proteins from procaryotic cells
CN107119095B (zh) 2008-01-03 2022-07-05 康乃尔研究基金会有限公司 原核生物中的糖基化蛋白表达
SG10201400320TA (en) 2008-02-20 2014-05-29 Glycovaxyn Ag Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells
HUE038456T2 (hu) 2009-11-19 2018-10-29 Glaxosmithkline Biologicals Sa Bioszintetikus rendszer, amely immunogén poliszaccharidokat termel prokarióta sejtekben
HUE037956T2 (hu) 2010-05-06 2018-09-28 Glaxosmithkline Biologicals Sa Kapszuláris Gram-pozitív bakteriális biokonjugátum vakcinák
US20150316549A2 (en) 2011-08-12 2015-11-05 Mario Feldman Method of diagnosing bacterial infections using bacterial glycoproteins
CA2847621A1 (en) 2011-09-06 2013-03-14 Glycovaxyn Ag Bioconjugate vaccines made in prokaryotic cells
US11193154B2 (en) 2011-11-04 2021-12-07 Cornell University Prokaryote-based cell-free system for the synthesis of glycoproteins
CA3125293A1 (en) 2012-11-07 2014-05-15 Glaxosmithkline Biologicals Sa Production of recombinant vaccine in e. coli by enzymatic conjugation
US9849169B2 (en) 2013-01-17 2017-12-26 Arsanis Biosciences Gmbh MDR E. coli specific antibody
BR112015025288B1 (pt) * 2013-04-05 2023-02-23 The Governors Of The University Of Alberta Composição de vacina para uso na vacinação de galinhas contra campylobacter
FI3110441T3 (fi) 2014-02-24 2024-05-06 Glaxosmithkline Biologicals Sa Uusi polysakkaridi ja sen käyttöjä
CN106794237B (zh) 2014-04-17 2022-04-12 葛兰素史密丝克莱恩生物有限公司 经修饰的宿主细胞及其用途
US10307474B2 (en) 2014-08-08 2019-06-04 Glaxosmithkline Biologicals S.A. Modified host cells and hybrid oligosaccharides for use in bioconjugate production
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
GB201704117D0 (en) * 2017-03-15 2017-04-26 London School Hygiene & Tropical Medicine Oligosaccharyl Transferase polypeptide
US11898187B2 (en) 2017-08-15 2024-02-13 Northwestern University Protein glycosylation sites by rapid expression and characterization of N-glycosyltransferases
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
US11530432B2 (en) 2018-03-19 2022-12-20 Northwestern University Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates
WO2019204346A1 (en) 2018-04-16 2019-10-24 Northwestern University METHODS FOR CO-ACTIVATING IN VITRO NON-STANDARD AMINO ACID (nsAA) INCORPORATION AND GLYCOSYLATION IN CRUDE CELLLYSATES
US12098433B2 (en) 2018-08-03 2024-09-24 Northwestern University On demand, portable, cell-free molecular sensing platform
WO2020044371A1 (en) * 2018-08-29 2020-03-05 Council Of Scientific And Industrial Research Recombinant microbial system for directed evolution of glycocins and a method of preparation thereof
US20220054632A1 (en) 2018-12-12 2022-02-24 Glaxosmithkline Biologicals Sa Modified carrier proteins for o-linked glycosylation
CA3126492A1 (en) * 2019-01-11 2020-07-16 Northwestern University Bioconjugate vaccines synthesis in prokaryotic cell lysates
WO2020191082A1 (en) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
AU2020240075A1 (en) 2019-03-18 2021-10-14 Janssen Pharmaceuticals, Inc. Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof
EP3757217A1 (en) 2019-06-27 2020-12-30 GlaxoSmithKline Biologicals S.A. Methods for protein purification
EP3770269A1 (en) 2019-07-23 2021-01-27 GlaxoSmithKline Biologicals S.A. Quantification of bioconjugate glycosylation
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
EP4168040A1 (en) 2020-06-18 2023-04-26 GlaxoSmithKline Biologicals S.A. Shigella-tetravalent (shigella4v) bioconjugate
WO2021259742A1 (en) 2020-06-25 2021-12-30 Glaxosmithkline Biologicals Sa Modified exotoxin a proteins
AU2021342797B2 (en) 2020-09-17 2024-02-08 Janssen Pharmaceuticals, Inc. Multivalent vaccine compositions and uses thereof
WO2023118033A1 (en) 2021-12-22 2023-06-29 Glaxosmithkline Biologicals Sa Vaccine
GB202302579D0 (en) 2023-02-23 2023-04-12 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3584198D1 (de) 1984-08-01 1991-10-31 Boehringer Ingelheim Int Neue genetische sequenzen, die durch sie codierten interferon-peptide vom typ i und diese sie produzierende organismen.
US5643758A (en) * 1987-03-10 1997-07-01 New England Biolabs, Inc. Production and purification of a protein fused to a binding protein
WO1994026906A2 (en) 1993-05-14 1994-11-24 The Upjohn Company CLONED DNA ENCODING A UDP-GALNAc:POLYPEPTIDE,N-ACETYLGALACTOS AMINYLTRANSFERASE
US6503744B1 (en) 1999-02-01 2003-01-07 National Research Council Of Canada Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics
AU3508300A (en) * 1999-03-02 2000-09-21 Human Genome Sciences, Inc. Engineering intracellular sialylation pathways
WO2001088117A2 (en) * 2000-05-12 2001-11-22 Neose Technologies, Inc. In vitro fucosylation recombinant glycopeptides
JP4092194B2 (ja) 2000-06-30 2008-05-28 フランダース インターユニバーシティ インスティテュート フォア バイオテクノロジー (ヴィーアイビー) ピキアパストリス(PichiaPastoris)におけるタンパク質糖鎖修飾
KR20090110951A (ko) 2002-03-07 2009-10-23 아이드게노쉬쉐 테흐니쉐 호흐슐레 쥬리히 원핵 숙주에서의 재조합 글리코실화 단백질 생산 방법 및 생산계
CA2818688A1 (en) 2002-03-07 2003-09-12 Eidgenossische Technische Hochschule Zurich System and method for the production of recombinant glycosylated proteins in a prokaryotic host
CA2494223C (en) 2002-08-01 2012-10-02 National Research Council Of Canada Campylobacter glycans and glycopeptides
EP2546260B1 (en) 2004-05-24 2015-07-15 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Live, oral vaccine for protection against shigella dysenteriae serotype 1
CA2607595C (en) 2005-05-11 2018-11-27 Eth Zuerich Recombinant n-glycosylated proteins from procaryotic cells
SG10201400320TA (en) 2008-02-20 2014-05-29 Glycovaxyn Ag Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells
HUE038456T2 (hu) * 2009-11-19 2018-10-29 Glaxosmithkline Biologicals Sa Bioszintetikus rendszer, amely immunogén poliszaccharidokat termel prokarióta sejtekben
HUE037956T2 (hu) * 2010-05-06 2018-09-28 Glaxosmithkline Biologicals Sa Kapszuláris Gram-pozitív bakteriális biokonjugátum vakcinák

Also Published As

Publication number Publication date
CA2477794C (en) 2013-08-20
US20140335127A1 (en) 2014-11-13
DE60303591T2 (de) 2007-03-01
US20050287628A1 (en) 2005-12-29
DK1481057T3 (da) 2006-05-15
AU2003205502A1 (en) 2003-09-16
US8703471B2 (en) 2014-04-22
WO2003074687A1 (en) 2003-09-12
ATE317897T1 (de) 2006-03-15
KR20090110951A (ko) 2009-10-23
CA2477794A1 (en) 2003-09-12
AU2003205502B2 (en) 2008-01-31
IL220322A0 (en) 2012-07-31
EP1481057A1 (en) 2004-12-01
AU2003205502C1 (en) 2011-08-25
EP1481057B1 (en) 2006-02-15
US20090074798A1 (en) 2009-03-19
IL163806A (en) 2012-08-30
IL163806A0 (en) 2005-12-18
DE60303591D1 (de) 2006-04-20
ES2258214T3 (es) 2006-08-16

Similar Documents

Publication Publication Date Title
PT1481057E (pt) Sistema e metodo para a producao de proteinas glicosiladas recombinantes num hospedeiro procariota
Smolskaya et al. Site-specific incorporation of unnatural amino acids into Escherichia coli recombinant protein: methodology development and recent achievement
Doi et al. Elongation factor Tu mutants expand amino acid tolerance of protein biosynthesis system
Roche et al. Identification of endogenous SsrA-tagged proteins reveals tagging at positions corresponding to stop codons
Donaldson et al. Sorting and signaling at the Golgi complex
Falck et al. Enzyme-based labeling strategies for antibody–drug conjugates and antibody mimetics
RU2473690C2 (ru) Генетически кодируемые флюоресцентные кумариновые аминокислоты
Yang et al. Chemical biology approaches for studying posttranslational modifications
MXPA04001566A (es) Un sistema para expresion y ensamblado de anticuerpos.
MX2008011669A (es) Expresion programada geneticamente de proteinas que contienen el aminoacido no natural fenilselenocisteina.
Shippy et al. tRNA modification enzymes GidA and MnmE: potential role in virulence of bacterial pathogens
DK1369486T3 (da) Plasmid-shuttlevektor mellem Escherichia coli og Brevibacillus
PT850310E (pt) Molecula de dna circular com origem de replicacao condicional, metodo para a sua preparacao e utilizacao da mesma na terapia genica
ATE328069T1 (de) Phosphopantethenyltransferasen und deren verwendungen
MX2007003142A (es) Incorporacion in vivo de alquinil aminoacidos a proteinas en eubacterias.
Fu et al. Marked difference in efficiency of the digestive enzymes pepsin, trypsin, chymotrypsin, and pancreatic elastase to cleave tightly folded proteins
Luxmi et al. Proteases shape the Chlamydomonas secretome: comparison to classical neuropeptide processing machinery
BR0207394A (pt) Proteìna de fusão para a secreção de uma proteìna de interesse no sobrenadante da cultura bacteriana
NO20042188D0 (no) Hydrolysert marint, proteinprodukt, fremgangsmate for produksjon derav, og anvendelse
DE60141769D1 (de) Verfahren zur herstellung von rekombinantem protein und fusionsprotein
MX2023007030A (es) Transposasas programables y usos de las mismas.
Linhorst et al. The human Ntn-hydrolase superfamily: structure, functions and perspectives
Gamblin et al. Chemical approaches to mapping the function of post‐translational modifications
BR0214542A (pt) Célula hospedeira, sistema de expressão, e, processos de preparação de uma célula hospedeira, e de uma proteìna alvo
PT96004A (pt) Processo para a producao de proteina nao fundida em e.coli